Loading page…

Nureca Limited (NURECA) · mywealthgrid

Nureca Limited

NSE:NURECA BSE:NURECA

HealthcareHealthcare Equipment & Supplies

₹349.9

-4.57%1 Oct close

Mkt cap

₹332 Cr

Watch Alert Compare

About

Nureca Limited operates in healthcare equipment supply, ₹323 Cr market cap. Promoter-controlled (68%), operates debt-free.

Face value: ₹10

Market cap

₹332 Cr

P/E

76.6×

P/B

1.8×

Dividend yield

ROE

1.1%

ROCE

3.3%

Debt / equity

OPM

0.1%

EPS (TTM)

₹4.5

Book value

₹189.5

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Profit volatility extreme: Q4 FY2026 -18% operating margin (₹-6.62 Cr loss) vs Q1 FY2027 +6–8%—raises questions on cost control and sustainability

PE multiple 74.49x very high relative to recent earnings, leaves minimal room for disappointing results

ROE chronically low at 1.11% despite recent profitability—capital not generating competitive returns

Revenue stable ₹35–40 Cr/quarter masks margin instability—verify whether profitability recovery is structural or temporary

Generated analysis · source review pending

Growth drivers

Operating margin recovered to 6–8% OPM in Q1 FY2027 from Q4 FY2026's -18% loss, indicating profit potential if recent improvement sustains

Revenue base stable ₹35–40 Cr/quarter provides scale if margin recovery stabilizes

Zero debt (D/E 0) preserves financial flexibility for growth investments or cyclical downturns

Healthcare equipment sector in India may expand with infrastructure investment and device adoption—verify TAM growth, competitive intensity, and pricing power

Generated analysis · source review pending

1,379 historical price candles were omitted because the exchange source has not been verified.

₹349.9-3.2%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+High promoter holding of 68.1% with no pledge

Cons

−Low return on equity of 0.2% (3-yr avg)
−Thin operating margin of 0.1%
−Profit declined 46.3% a year over the last 5 years
−Revenue shrank over the last 5 years (-7.2% a year)
−Expensive at 76.6× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

40/100

Business quality: 26
Growth: 72
Valuation: 24

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	213	256	111	92	110	147
COGS	99	133	76	61	68	93
Gross profit	114	123	36	31	42	54
	52	67	51	42	49	54
	62	56	-15	-10	-8	0
OPM %	28.8%	21.7%	-13.5%	-11.1%	-6.9%	0.1%
Depreciation	0	1	2	2	2	2
Interest	2	1	0	0	1	1
	3	8	7	11	12	8
Profit before tax	62	61	-11	-3	1	5
Tax	16	16	-2	-1	1	3
Tax %	25.6%	26.3%	-23.2%	-29.5%	37.3%	58.2%
	46	45	-8	-2	1	2
PAT margin %	21.7%	17.6%	-7.4%	-2%	0.8%	1.4%
EPS (₹)	62	45	-8.3	-1.8	0.9	2.1
EPS adjusted (₹)	46.4	45	-8.3	-1.8	0.9	2.2
	3.2%	6.7%	—	—	0%	—
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	—	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	10	10	10	10
Reserves	153	193	185	183	184	171
	4	1	3	0	2	1
	19	15	8	12	13	15
Total equity & liabilities	186	219	207	205	210	196
	4	10	9	5	7	12
CWIP	—	—	0	0	0	0
Investments	0	33	59	94	1	1
	182	176	139	106	202	183
Total assets	186	219	207	205	210	196

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	53.4%	48.1%	32.2%	34.1%	38%	36.9%
EBITDA margin %	28.8%	21.7%	-13.5%	-11.1%	-6.9%	0.1%
EBIT margin %	28.6%	21.1%	-15.6%	-13.7%	-9%	-1.3%
PAT margin %	21.7%	17.6%	-7.4%	-2%	0.8%	1.4%
Working capital
Receivable days	0	4	14	6	11	19
Inventory days	135	174	167	186	214	187
Payable days	32	13	24	31	35	20
NWC days	103	165	157	161	190	186
Leverage
Current ratio	9.6	16.85	21.01	20.78	15.32	8.32
Debt to EBITDA	0.06	0.02	—	—	—	4
Debt to equity	0.02	0.01	0.02	0	0.01	0
Interest coverage	40	83.4	-22.9	-4.2	2.1	4.9
Asset turnover	1.15	1.17	0.54	0.45	0.52	0.75
Return ratios
Return on assets %	25%	20.5%	-4%	-0.9%	0.4%	1.1%
Return on capital employed %	38.3%	33%	-5.1%	-1%	1.3%	3.3%
Return on equity %	28.4%	22.1%	-4.2%	-0.9%	0.4%	1.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	63.24%	63.24%	63.24%	63.24%	63.77%	64.06%	64.3%	64.33%	64.97%	64.97%	68.09%	68.09%
	0.1%	0.07%	0.07%	0.07%	0.69%	0.36%	1.07%	0.07%	0.07%	0.08%	0.28%	0.11%
	0.02%	0.02%	0.02%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.24%	0.24%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	36.64%	36.67%	36.67%	36.65%	35.5%	35.54%	34.59%	35.56%	34.92%	34.91%	31.39%	31.56%
No. of shareholders	—	—	—	—	—	—	—	—	37,468	35,801	34,558	33,979

Promoter holding up 4.85 percentage points since Sep 2023.

217 deals · 4 Aug 2021 – 29 Oct 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
29 Oct 2025	SWATHITHA SIVAKUMAR	Bulk	NSE	Sell	77,761	₹263.96	₹2.05 Cr
15 Jan 2025	COPTHALL MAURITIUS INVESTMENT LIMITED	Bulk	NSE	Buy	1,16,711	₹401.94	₹4.69 Cr
15 Jan 2025	AAKRAYA RESEARCH LLP	Bulk	NSE	Sell	63,937	₹409.84	₹2.62 Cr
15 Jan 2025	AAKRAYA RESEARCH LLP	Bulk	NSE	Buy	63,937	₹409.49	₹2.62 Cr
14 Jan 2025	ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED	Bulk	NSE	Sell	65,679	₹363.99	₹2.39 Cr
14 Jan 2025	ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED	Bulk	NSE	Buy	51,679	₹360.28	₹1.86 Cr
10 Jan 2025	N V INVESTMENTS	Bulk	NSE	Buy	1,58,000	₹358.81	₹5.67 Cr
10 Jan 2025	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Sell	95,867	₹362.41	₹3.47 Cr
10 Jan 2025	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Buy	95,867	₹362.11	₹3.47 Cr
10 Jan 2025	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	64,563	₹367.89	₹2.38 Cr

1–10 of 217

1 / 22

Mr. SAURABH GOYALExecutive Director-Chairperson related to Promoter-MD
Mr. VIJAY KUMAR SHARMANon-Executive - Independent Director
Ms. CHARU SINGHNon-Executive - Independent Director
Ms. RUCHITA AGARWALNon-Executive - Independent Director
Mr. ARYAN GOYALExecutive Director
Mr. RAJINDER SHARMAExecutive Director
Mr. RUPINDER TEWARINon-Executive - Independent Director
Mr. KULDIP KUMAR BHASINNon-Executive - Independent Director
Ms. SMITA GOYALExecutive Director
Mr. Chander KantChief Financial Officer
Mrs. Nishu KansalCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Nureca Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Interim dividend24 Feb 2022 · ex-date₹3
Final dividend21 Sept 2021 · ex-date₹2

1

Board meeting to consider results21 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

34 announcementsExport CSV

1 Oct 2026, 11:53 amCompany Update

Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')

General PDF

30 Sept 2026, 12:17 pmCompany Update

Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')

General PDF

29 Sept 2026, 4:16 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

29 Sept 2026, 12:32 pmCompany Update

Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')

General PDF

28 Sept 2026, 11:39 amCompany Update

Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')

General PDF

10 Sept 2026, 4:00 pmCompany Update

"Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 (PIT Regulations)''''

General PDF

10 Sept 2026, 9:46 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

10 Sept 2026, 9:36 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

Date	Category	Subject	Filing
1 Oct 2026, 11:53 am	Company Update General	Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')	PDF
30 Sept 2026, 12:17 pm	Company Update General	Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	53.4%	48.1%	32.2%	34.1%	38%	36.9%
EBITDA margin %	28.8%	21.7%	-13.5%	-11.1%	-6.9%	0.1%
EBIT margin %	28.6%	21.1%	-15.6%	-13.7%	-9%	-1.3%
PAT margin %	21.7%	17.6%	-7.4%	-2%	0.8%	1.4%
Working capital
Receivable days	0	4	14	6	11	19
Inventory days	135	174	167	186	214	187
Payable days	32	13	24	31	35	20
NWC days	103	165	157	161	190	186
Leverage
Current ratio	9.6	16.85	21.01	20.78	15.32	8.32
Debt to EBITDA	0.06	0.02	—	—	—	4
Debt to equity	0.02	0.01	0.02	0	0.01	0
Interest coverage	40	83.4	-22.9	-4.2	2.1	4.9
Asset turnover	1.15	1.17	0.54	0.45	0.52	0.75
Return ratios
Return on assets %	25%	20.5%	-4%	-0.9%	0.4%	1.1%
Return on capital employed %	38.3%	33%	-5.1%	-1%	1.3%	3.3%
Return on equity %	28.4%	22.1%	-4.2%	-0.9%	0.4%	1.2%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Molbio Diagnostics LimitedMOLBIOMOLBIO	₹17,431 Cr	₹17,844 Cr	₹1,020 Cr	₹262 Cr	25.7%	₹145 Cr	13.6%	23.7%	16.2%	—
Poly Medicure LimitedPOLYMEDPOLYMED	₹16,610 Cr	₹16,952 Cr	₹1,997 Cr	₹461 Cr	23.6%	₹315 Cr	17.1%	14.5%	11%	294
Fischer Medical Ventures LimitedFISCHERFISCHER	₹2,190 Cr	₹2,262 Cr	₹367 Cr	₹50 Cr	14%	₹30 Cr	10.1%	13.6%	8.6%	111
Tarsons Products LimitedTARSONSTARSONS	₹1,752 Cr	₹2,135 Cr	₹441 Cr	₹119 Cr	27.9%	₹11 Cr	3.4%	5%	2.3%	361
Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL	₹1,066 Cr	₹1,066 Cr	₹287 Cr	₹46 Cr	15.6%	₹31 Cr	10.4%	14.7%	12.8%	109
Hemant Surgical Industries LtdHSILHSIL	₹885 Cr	—	₹232 Cr	₹23 Cr	10%	₹18 Cr	7.9%	—	—	—
Fabtech Technologies LimitedFABTECHFABTECH	₹632 Cr	₹675 Cr	₹418 Cr	₹45 Cr	8.5%	₹49 Cr	9.3%	15.5%	12.9%	55
Prevest Denpro LtdPREVESTPREVEST	₹452 Cr	—	₹72 Cr	₹25 Cr	34.4%	₹20 Cr	28.5%	—	—	—
Nureca LimitedNURECANURECA	₹332 Cr	₹333 Cr	₹153 Cr	₹4 Cr	0.1%	₹4 Cr	1.4%	3.3%	1.1%	186
Earkart LtdEARKARTEARKART	₹179 Cr	₹179 Cr	₹54 Cr	₹8 Cr	15.5%	₹5 Cr	9.1%	12.1%	7.7%	243
Choksi Asia LtdCHOKSICHOKSI	₹117 Cr	₹119 Cr	₹11 Cr	₹-2 Cr	13.8%	₹2 Cr	10.8%	18.9%	13.5%	142
Shree Pacetronix LtdSHREEPACSHREEPAC	₹68 Cr	₹71 Cr	₹8 Cr	₹1 Cr	23.5%	₹0 Cr	14%	27.4%	18.9%	385

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	35	1	10	-3	-19	3
	-110	-3	-16	18	8	14
	92	-7	-2	-1	-0	-20
Net cash flow	17	-9	-8	14	-11	-2
Free cash flow	34	-2	10	-4	-23	-4
CFO / Operating profit %	56.7%	2.5%	—	—	—	—

Nureca Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

2

1

Announcements

2

1

No fund holdings on record

Not in the F&O segment

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Nureca Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends2

Board meetings1

Announcements

Dividends2

Board meetings1

Ratio timeline

No fund holdings on record

Not in the F&O segment

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

2

1

2

1